NASDAQ:GCTK GlucoTrack (GCTK) Stock Price, News & Analysis $0.29 +0.07 (+30.81%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends About GlucoTrack Stock (NASDAQ:GCTK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GlucoTrack alerts:Sign Up Key Stats Today's Range$0.22▼$0.2950-Day Range$0.22▼$2.1852-Week Range$0.20▼$4.95Volume513,890 shsAverage Volume143,353 shsMarket Capitalization$1.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.Read More… GlucoTrack Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks34th Percentile Overall ScoreGCTK MarketRank™: GlucoTrack scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for GlucoTrack. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of GlucoTrack is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GlucoTrack is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlucoTrack has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.10% of the float of GlucoTrack has been sold short.Short Interest Ratio / Days to CoverGlucoTrack has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GlucoTrack has recently decreased by 66.74%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGlucoTrack does not currently pay a dividend.Dividend GrowthGlucoTrack does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.10% of the float of GlucoTrack has been sold short.Short Interest Ratio / Days to CoverGlucoTrack has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GlucoTrack has recently decreased by 66.74%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News SentimentN/A News SentimentGlucoTrack has a news sentiment score of 1.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for GlucoTrack this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for GCTK on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GlucoTrack insiders have not sold or bought any company stock.Percentage Held by Insiders46.50% of the stock of GlucoTrack is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.92% of the stock of GlucoTrack is held by institutions.Read more about GlucoTrack's insider trading history. Receive GCTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlucoTrack and its competitors with MarketBeat's FREE daily newsletter. Email Address GCTK Stock News HeadlinesGlucoTrack Enters Sales Agreement with Dawson James SecuritiesOn December 17, 2024, GlucoTrack, Inc. (NASDAQ:GCTK) announced the signing of an At-the-Market (ATM) sales agreement with Dawson James Securities, Inc. ("Dawson James"). The agreement invoDecember 19 at 4:17 AM | americanbankingnews.comGlucoTrack announces start of enrollment for human clinical study of CBGMDecember 3, 2024 | markets.businessinsider.comCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.December 21, 2024 | Brownstone Research (Ad)GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITORDecember 3, 2024 | globenewswire.comGlucoTrack Completes Funding to Enhance Financial StabilityNovember 16, 2024 | markets.businessinsider.comGlucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding DebtNovember 14, 2024 | globenewswire.comUnited States shares mixed at close of trade; Dow Jones Industrial Average up 0.11%November 13, 2024 | msn.comGlucotrack, Inc. Announces Pricing of $10.0 Million Public OfferingNovember 13, 2024 | markets.businessinsider.comSee More Headlines GCTK Stock Analysis - Frequently Asked Questions How have GCTK shares performed this year? GlucoTrack's stock was trading at $1.3075 at the beginning of the year. Since then, GCTK shares have decreased by 77.8% and is now trading at $0.29. View the best growth stocks for 2024 here. When did GlucoTrack's stock split? GlucoTrack shares reverse split before market open on Monday, May 20th 2024. The 1-5 reverse split was announced on Monday, May 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of GlucoTrack? Shares of GCTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of GlucoTrack own? Based on aggregate information from My MarketBeat watchlists, some other companies that GlucoTrack investors own include Rolls-Royce Holdings plc (RYCEY), Blink Charging (BLNK), Cameco (CCJ), Cybin (CYBN), Cyclo Therapeutics (CYTH), Ford Motor (F) and iShares U.S. Infrastructure ETF (IFRA). Company Calendar Today12/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:GCTK CUSIPN/A CIK1506983 Webwww.glucotrack.com Phone(201) 842-7715Fax972-8675-7850Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,100,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-826.43% Return on Assets-707.26% Debt Debt-to-Equity Ratio0.52 Current Ratio0.14 Quick Ratio0.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book0.38Miscellaneous Outstanding Shares5,772,000Free Float5,408,000Market Cap$1.67 million OptionableNot Optionable Beta-0.17 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:GCTK) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlucoTrack, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlucoTrack With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.